Investigational PD-1 Inhibitors in HL and NHL and Biomarkers for Predictors of Response and Outcome

Overview

Journal Expert Opin Investig Drugs

Specialty Pharmacology

Date 2017 Dec 13

PMID 29228840

Citations 3

Authors

Andres Chang

Danielle Schlafer

Christopher R Flowers

Pamela B Allen

Affiliations

Soon will be listed here.

Abstract

Introduction: Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies.

Areas Covered: We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgkin lymphomas, and potential predictors of response.

Expert Opinion: We anticipate that in the next 10 years, agents that modulate the immune system such as PD-1 antagonists will be increasingly used in favor over traditional cytotoxic chemotherapeutic agents. PD-1 antagonists will be combined with future immunotherapies or used as adjuncts to cellular therapy to boost tumor-specific immune responses.

Citing Articles

CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies.

Su M, Zhang Z, Jiang P, Wang X, Tong X, Wu G Cell Transplant. 2024; 33:9636897241293964.

PMID: 39506457 PMC: 11693693. DOI: 10.1177/09636897241293964.

Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics.

Wang Y, Zhang M, Xue Q, Zhou H, Chen J, Wang H Front Immunol. 2023; 14:1172307.

PMID: 37138889 PMC: 10149821. DOI: 10.3389/fimmu.2023.1172307.

Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.

Quach H, Hou Z, Bellis R, Saini J, Amador-Molina A, Adusumilli P Expert Opin Investig Drugs. 2022; 31(11):1187-1202.

PMID: 36448335 PMC: 10085570. DOI: 10.1080/13543784.2022.2152323.

References

Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H . Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017; 129(18):2471-2478. DOI: 10.1182/blood-2016-11-749556. View

Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-28. DOI: 10.1056/NEJMoa1501824. View

Green M, Rodig S, Juszczynski P, Ouyang J, Sinha P, ODonnell E . Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012; 18(6):1611-8. PMC: 3321508. DOI: 10.1158/1078-0432.CCR-11-1942. View

Sfeir J, Drake M, LaPlant B, Maurer M, Link B, Berndt T . Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia. Blood Cancer J. 2017; 7(2):e526. PMC: 5386343. DOI: 10.1038/bcj.2017.9. View

Ding W, LaPlant B, Call T, Parikh S, Leis J, He R . Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017; 129(26):3419-3427. PMC: 5492091. DOI: 10.1182/blood-2017-02-765685. View

Roemer M, Advani R, Redd R, Pinkus G, Natkunam Y, Ligon A . Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunol Res. 2016; 4(11):910-916. PMC: 5210180. DOI: 10.1158/2326-6066.CIR-16-0201. View

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A . Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291(5502):319-22. DOI: 10.1126/science.291.5502.319. View

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

Oestreich K, Yoon H, Ahmed R, Boss J . NFATc1 regulates PD-1 expression upon T cell activation. J Immunol. 2008; 181(7):4832-9. PMC: 2645436. DOI: 10.4049/jimmunol.181.7.4832. View

10.

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T . Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. PMC: 4279952. DOI: 10.1038/nature13988. View

11.

Hwang Y, Khong P, Kwong Y . Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma. Ann Hematol. 2017; 96(7):1219-1220. DOI: 10.1007/s00277-017-3007-9. View

12.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

13.

Patsoukis N, Sari D, Boussiotis V . PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle. 2012; 11(23):4305-9. PMC: 3552912. DOI: 10.4161/cc.22135. View

14.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

15.

Sugita S, Usui Y, Horie S, Futagami Y, Yamada Y, Ma J . Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism. Invest Ophthalmol Vis Sci. 2008; 50(1):263-72. DOI: 10.1167/iovs.08-2536. View

16.

Twa D, Chan F, Ben-Neriah S, Woolcock B, Mottok A, Tan K . Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014; 123(13):2062-5. DOI: 10.1182/blood-2013-10-535443. View

17.

Weber J, Postow M, Lao C, Schadendorf D . Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Oncologist. 2016; 21(10):1230-1240. PMC: 5061539. DOI: 10.1634/theoncologist.2016-0055. View

18.

Myklebust J, Irish J, Brody J, Czerwinski D, Houot R, Kohrt H . High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013; 121(8):1367-76. PMC: 3578953. DOI: 10.1182/blood-2012-04-421826. View

19.

Wherry E, Barber D, Kaech S, Blattman J, Ahmed R . Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A. 2004; 101(45):16004-9. PMC: 524220. DOI: 10.1073/pnas.0407192101. View

20.

Younes A, Santoro A, Shipp M, Zinzani P, Timmerman J, Ansell S . Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016; 17(9):1283-94. PMC: 5541855. DOI: 10.1016/S1470-2045(16)30167-X. View